Send by Xconomy

Investors are fuming today about the surprise rejection of the once-weekly diabetes drug developed by San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN), [...]

Send by Beacon Equity Research

Amylin stock plunged after the company announced the receipt of a complete response letter from the US FDA relating to the New Drug Application (NDA) for [...]

Send by TheStreet.com

By TheStreet Staff 10/20/10 - 09:32 AM EDT Amylin Pharmaceuticals (AMLN) downgraded at Credit Suisse to Neutral from Outperform. Bydureon delay reduces peak [...]

Send by Wall Street Journal

Among the companies whose shares are actively trading in the session are Yahoo Inc. (YHOO), Amylin Pharmaceuticals Inc. (AMLN) and Morgan Stanley (MS). [...]

Send by MedPage Today

The latest response did not bring the manufacturing issue up again, but Amylin and Lilly noted that discussions over finalization of the product labeling [...]

Send by Wall Street Journal (blog)

Also, investors may have been betting that the Food and Drug Administration would approve a new diabetes drug developed by Amylin, Eli Lilly and Alkermes [...]

Send by Financial Times

Regulators said they wanted more data from New York-listed drugmakers Amylin and Eli Lilly before they accepted the drug Bydureon, a move that will delay [...]

Amylin Pharmaceuticals and Eli Lilly and Company jointly developed and launched Byetta®, approved by the FDA in April 2005 as adjunctive therapy to improve [...]

amylin's favorite photos from other Flickr members (645) amylin doesn't have any testimonials yet. Joined: May 2005. Currently: istanbul, türkiye [...]

Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results [...]

18 Jun 2010 Amylin Pharmaceuticals Inc. rose the most in almost five years in Nasdaq trading after a competitor to its Byetta diabetes treatment was [...]

Challenging science and changing lives—it's the way of life at Amylin, where more than 1500 extraordinarily dedicated men and women are working to improve [...]

20 Oct 2010 NEW YORK (Reuters) - Amylin Pharmaceuticals' shares lost half their value on Wednesday, after US regulators declined to approve the [...]

NEW YORK (Market Intellisearch) -- AMLN options saw interesting call activity today. A total of 632 put and 1908 call contracts were traded raising a low Put/Call volume alert. Today's traded Put Related Symbols: NASDAQ:AMLN. [...]

Bio-Synthesis Inc. is a leading life science products company which deals in Custom Peptide Synthesis, Services Amylin Peptides, Trojan Peptides, Oxygen Peptide, Peptide Synthesis Chemistry and Amyloid Beta Peptides. 1 Vote(s) [...]

Send by Maureen Martino

Amylin, Eli Lilly and Alkermes have received an FDA complete response letter for Bydureon, but the companies note in an announcement that there are no requests for new pre-clinical or clinical Read more [...]

Send by The Options Insider

ALKS is a partner with Amylin (AMLN) and Eli Lilly (LLY) on the drug. Shares are down 29 percent to $10.31. Meanwhile, although shares are volatile today, [...]

Send by marketmaker

Reuters - Amylin Pharmaceuticals' shares lost half their value in premarket trading on Wednesday, after U.S. regulators declined to approve its long-acting diabetes drug until more data is obtained on its potential effect on heart rates [...]

SAN DIEGO, April 19, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2010. The Company reported total revenue of $174.1 million for the quarter ended March 31, [...]

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug [...]

Send by www.businessweek.com

Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. dropped in trading after they were rebuffed a second time in a bid to gain U.S. approval of a once- weekly version of the diabetes drug Byetta. [...]

Send by Bloomberg

Amylin Pharmaceuticals Inc. (AMLN US) plunged 50 percent to $10.16. The maker of the diabetes treatment Byetta canceled a quarterly-update conference call [...]

Send by Franklin Price

Unconfirmed rumor that Amylin Pharmaceuticals, Inc. (AMLN) will be taken out by Eli Lilly & Co. (LLY) at $32.00. Neither company could be reached for comment..(AMLN)(LLY) [...]

Send by David Phillips

Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important US market. The Danish drug maker's early commercial success with its subcutaneous [...]

One of the hottest trends in bathroom vanities are those called floating vanities. Although the term might conjure up visions or flying carpets and clouds, floating bathroom vanities are very much anchored into your room’s décor. The term is only used because the vanities, unlike most of their prede [...]